«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 05

Page:

958-962

Research Field:

Publishing date:

Info

Title:

Current status of research on improving the efficacy of immunotherapy by regulating the tumour immune microenvironment with traditional Chinese medicine based on the discussion of gut microbiota

Author(s):

MAO Qiyuan¹; FAN Huiting¹; WANG Xueqian¹; JIANG Lingli¹; ZHANG Peng²; LI Daorui¹; LIN Hongsheng¹

1.Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China£»2.Department of TCM Rehabilitation,Shangdang District People's Hospital,Changzhi city£¬Shanxi Changzhi 047100£¬China.

Keywords:

gut microbiota; traditional Chinese medicine; tumour immune microenvironment; immunotherapy; research status

PACS:

R730.51

DOI:

10.3969/j.issn.1672-4992.2024.05.030

Abstract:

Although immunotherapy,represented by immune checkpoint inhibitors,has brought survival benefits to some patients with malignant tumours,there are still problems that should not be ignored,among which the low response rate of immunotherapy limits its clinical application.In recent years,gut microbiota is increasingly considered as one of the important predictive biomarkers of immunotherapy efficacy,and the regulation of the tumour immune microenvironment is one of the important mechanisms of action.Traditional Chinese medicine (TCM) is a representative of complementary medicine in China,and oral TCM has a regulatory effect on gut microbiota,and its improvement of the tumour immune microenvironment and the efficacy of immunotherapy is also highly concerned by the oncology community.Based on the gut microbiota,this paper will summarise and discuss the current status of research on the regulation of the tumour immune microenvironment by TCM to improve the efficacy of immunotherapy,with a view to providing a theoretical basis for the synergistic effect of TCM and immunotherapy,and providing ideas for further basic and clinical research.

References:

£Û1£ÝFITZMAURICE C,ABATE D,ABBASI N,et al.Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2017:A systematic analysis for the global burden of disease study£ÛJ£Ý.JAMA Oncol,2019,5(12):1749-1768.
£Û2£ÝPAZ-ARES LG,CIULEANU TE,PLUZANSKI A,et al.Safety of first-line nivolumab plus ipilimumab in patients with metastatic nsclc:A pooled analysis of checkmate 227,checkmate 568,and checkmate 817£ÛJ£Ý.J Thorac Oncol,2023,18(1):79-92.
£Û3£ÝVOKES EE,READY N,FELIP E,et al.Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057):3-year update and outcomes in patients with liver metastases£ÛJ£Ý.Ann Oncol,2018,29(4):959-965.
£Û4£ÝSMYTH EC,GAMBARDELLA V,CERVANTES A,et al.Checkpoint inhibitors for gastroesophageal cancers:dissecting heterogeneity to better understand their role in first-line and adjuvant therapy£ÛJ£Ý.Ann Oncol,2021,32(5):590-599.

£Û5£ÝLE DT,KIM TW,VAN CUTSEM E,et al.Phase II open-label study of pembrolizumab in treatment-refractory,microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer:KEYNOTE-164 £ÛJ£Ý.J Clin Oncol,2020,38(1):11-19.
£Û6£ÝOVERMAN MJ,MCDERMOTT R,LEACH JL,et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142):An open-label,multicentre,phase 2 study£ÛJ£Ý.Lancet Oncol ,2017,18(9):1182-1191.
£Û7£ÝYAU T,HSU C,KIM TY,et al.Nivolumab in advanced hepatocellular carcinoma:Sorafenib-experienced Asian cohort analysis £ÛJ£Ý.J Hepatol,2019,71(3):543-552.
£Û8£ÝALBIGES L,TANNIR NM,BUROTTO M,et al.First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial £ÛJ£Ý.Eur Urol,2022,81(3):266-271.
£Û9£ÝMOTZER RJ,ESCUDIER B,GEORGE S,et al.Nivolumab versus everolimus in patients with advanced renal cell carcinoma:Updated results with long-term follow-up of the randomized,open-label,phase 3 CheckMate 025 trial £ÛJ£Ý.Cancer,2020,126(18):4156-4167.
£Û10£ÝWEBER JS,D'ANGELO SP,MINOR D,et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):A randomised,controlled,open-label,phase 3 trial £ÛJ£Ý.Lancet Oncol,2015,16(4):375-384.
£Û11£ÝHODI FS,CHESNEY J,PAVLICK AC,et al.Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma:2-year overall survival outcomes in a multicentre,randomised,controlled,phase 2 trial£ÛJ£Ý.Lancet Oncol,2016,17(11):1558-1568.
£Û12£ÝGIULIANI M,POGGI A.Checkpoint inhibitors and engineered cells:New weapons for natural killer cell arsenal against hematological malignancies £ÛJ£Ý.Cells,2020,9(7):1578.
£Û13£ÝGALSKY MD,BAJORIN DF,WITJES JA,et al.Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized checkmate 274 trial by PD-L1 combined positive score and tumor cell score£ÛJ£Ý.Eur Urol,2023,83(5):432-440.
£Û14£ÝROBERT C,LONG GV,BRADY B,et al.Nivolumab in previously untreated melanoma without BRAF mutation £ÛJ£Ý.N Engl J Med,2015,372(4):320-330.
£Û15£ÝLARKIN J,CHIARION-SILENI V,GONZALEZ R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma £ÛJ£Ý.N Engl J Med,2015,373(1):23-34.
£Û16£ÝSPAIN L,DIEM S,LARKIN J.Management of toxicities of immune checkpoint inhibitors £ÛJ£Ý.Cancer Treat Rev,2016,44:51-60.
£Û17£ÝFUENTES-ANTR¦BS J,PROVENCIO M,D¦PAZ-RUBIO E.Hyperprogression as a distinct outcome after immunotherapy £ÛJ£Ý.Cancer Treat Rev,2018,70:16-21.
£Û18£ÝSA¦GDA-BOUZID E,DEFAUCHEUX C,KARABAJAKIAN A,et al.Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma £ÛJ£Ý.Ann Oncol,2017,28(7):1605-1611.
£Û19£ÝBORCOMAN E,KANJANAPAN Y,CHAMPIAT S,et al.Novel patterns of response under immunotherapy £ÛJ£Ý.Ann Oncol,2019,30:385-396.
£Û20£ÝKIM CG,KIM KH,PYO KH,et al.Hyperprogressive disease during PD- 1/PD- L1 blockade in patients with non- small- cell lung cancer £ÛJ£Ý.Ann Oncol,2019,30:1104-1113.
£Û21£ÝO'DONNELL JS,LONG GV,SCOLYER RA,et al.Resistance to PD1/PDL1 checkpoint inhibition£ÛJ£Ý.Cancer Treat Rev,2017,52:71-81.
£Û22£ÝSIVAN A,CORRALES L,HUBERT N,et al.Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy £ÛJ£Ý.Science,2015,350(6264):1084-1089.
£Û23£ÝCHEN HM,LIU XW,SUN RJ,et al.A survey on the developmental intestinal microbiota research in China:The history,funding,and frontiers of gut bacteria £ÛJ£Ý.J Dig Dis,2015,16(8):421-430.
£Û24£ÝGAGLIANI N,HU B,HUBER S,et al.The fire within:Microbes inflame tumors.£ÛJ£Ý.Cell ,2014,157(4):776-783.
£Û25£ÝV¦ITIZOU M,PITT JM,DAILL¦KRE R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota £ÛJ£Ý.Science,2015,350(6264):1079-1084.
£Û26£ÝROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors £ÛJ£Ý.Science,2018,359(6371):91-97.
£Û27£ÝMATSON V,FESSLER J,BAO R,et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients £ÛJ£Ý.Science,2018,359(6371):104-108.
£Û28£ÝGOPALAKRISHNAN V,SPENCER CN,NEZI L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients £ÛJ£Ý.Science,2018,359(6371):97-103.
£Û29£ÝCHAPUT N,LEPAGE P,COUTZAC C,et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab £ÛJ£Ý.Ann Oncol,2017,28(6):1368-1379.
£Û30£ÝDEROSA L,HELLMANN MD,SPAZIANO M,et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer£ÛJ£Ý.Ann Oncol,2018,29(6):1437-1444.
£Û31£ÝENG L,SUTRADHAR R,NIU Y,et al.Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer:A population-based study£ÛJ£Ý.J Clin Oncol,2023,41(17):3122-3134.
£Û32£ÝSHOJI F,YAMAGUCHI M,OKAMOTO M,et al.Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer £ÛJ£Ý.Front Mol Biosci,2022,9:1040424.
£Û33£ÝLIOU JM,LEE YC,EL-OMAR EM,et al.Pylori eradication for gastric cancer prevention £ÛJ£Ý.Cancers (Basel),2019,11(5):593.
£Û34£ÝHE C,PENG C,XU X,et al.Probiotics mitigate helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota £ÛJ£Ý.Helicobacter,2022,27(4):e12898.
£Û35£ÝZHENG C,CHEN T,WANG Y,et al.A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer £ÛJ£Ý.J Cancer,2019,10(3):568-576.
£Û36£ÝBINNEWIES M,ROBERTS EW,KERSTEN K,et al.Understanding the tumor immune microenvironment (TIME) for effective therapy £ÛJ£Ý.Nat Med,2018,24(5):541-550.
£Û37£ÝARNETH B.Tumor microenvironment £ÛJ£Ý.Medicina (Kaunas),2019,56(1):15.
£Û38£ÝGALLI F,AGUILERA JV,PALERMO B,et al.Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy £ÛJ£Ý.J Exp Clin Cancer Res,2020,39(1):89.
£Û39£ÝSUN JY,YIN TL,ZHOU J,et al.Gut microbiome and cancer immunotherapy £ÛJ£Ý.J Cell Physiol,2020,235(5):4082-4088.
£Û40£ÝANSALDO E,SLAYDEN LC,CHING KL,et al.Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis £ÛJ£Ý.Science,2019,364(6446):1179-1184.
£Û41£ÝDAILL¦KRE R,V¦ITIZOU M,WALDSCHMITT N,et al.Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects£ÛJ£Ý.Immunity,2016,45(4):931-943.
£Û42£ÝSHI Y,ZHENG W,YANG K,et al.Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling £ÛJ£Ý.J Exp Med,2020,217(5):e20192282.
£Û43£ÝLI Y,TINOCO R,ELM¦IN L,et al.Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice £ÛJ£Ý.Nat Commun,2019,10(1):1492.
£Û44£ÝBESSELL CA,ISSER A,HAVEL JJ,et al.Commensal bacteria stimulate antitumor responses via T cell cross-reactivity £ÛJ£Ý.JCI Insight,2020,5(8):e135597.
£Û45£ÝFLUCKIGER A,DAILL¦KRE R,SASSI M,et al.Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage £ÛJ£Ý.Science,2020,369(6506):936-942.
£Û46£ÝGRIFFIN ME,ESPINOSA J,BECKER JL,et al.Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy £ÛJ£Ý.Science,2021,373(6558):1040-1046.
£Û47£ÝCHAI JN,PENG Y,RENGARAJAN S,et al.Helicobacter species are potent drivers of colonic T cell responses in homeostasis and inflammation £ÛJ£Ý.Sci Immunol,2017,2(13) pii:2/13/eaal5068.
£Û48£ÝGUR C,IBRAHIM Y,ISAACSON B,et al.Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack £ÛJ£Ý.Immunity,2015,42(2):344-355.
£Û49£ÝTHIELE ORBERG E,FAN H,TAM AJ,et al.The myeloid immune signature of enterotoxigenic bacteroides fragilis-induced murine colon tumorigenesis £ÛJ£Ý.Mucosal Immunol,2017,10(2):421-433.
£Û50£ÝLI T,HAN L,MA S,et al.Interaction of gut microbiota with the tumor microenvironment:A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer £ÛJ£Ý.Front Mol Biosci,2023,10:1140325.
£Û51£ÝLYU J,JIA Y,LI J,et al.Gegen qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment £ÛJ£Ý.Cell Death Dis,2019,10(6):415.
£Û52£ÝSUI H,ZHANG L,GU K,et al.YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation £ÛJ£Ý.Cell Commun Signal,2020,18(1):113.
£Û53£ÝSHI HJ,CHEN XY,CHEN XR,et al.Chinese medicine formula siwu-yin inhibits esophageal precancerous lesions by improving intestinal flora and macrophage polarization£ÛJ£Ý.Front Pharmacol,2022,13:812386.
£Û54£ÝQIU W,SANG T,CHEN H,et al.Wenzi jiedu recipe ameliorates colorectal cancer by remodeling the gut microbiota and tumor microenvironment £ÛJ£Ý.Front Oncol,2022,12:915498.
£Û55£ÝWANG Y,ZHANG X,LI J,et al.Sini decoction ameliorates colorectal cancer and modulates the composition of gut microbiota in mice£ÛJ£Ý.Front Pharmacol,2021,12:609992.
£Û56£ÝNIE X,GENG Z,LIU J,et al.Chinese herbal medicine anticancer cocktail soup activates immune cells to kill colon cancer cells by regulating the gut microbiota-Th17 axis £ÛJ£Ý.Front Pharmacol,2022,13:963638.
£Û57£ÝHUANG J,LIU D,WANG Y,et al.Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio,potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy £ÛJ£Ý.Gut,2022,71(4):734-745.
£Û58£ÝQU L,MA X,FAN D.Ginsenoside Rk3 suppresses hepatocellular carcinoma development through targeting the Gut-liver axis £ÛJ£Ý.J Agric Food Chem,2021,69(35):10121-10137.
£Û59£ÝKHAN I,HUANG G,LI XA,et al.Mushroom polysaccharides and jiaogulan saponins exert cancer preventive effects by shaping the gut microbiota and microenvironment in ApcMin/+ mice £ÛJ£Ý.Pharmacol Res,2019,148:104448.
£Û60£ÝWU X,CAO J,LI M,et al.An integrated microbiome and metabolomic analysis identifies immunoenhancing features of Ganoderma lucidum spores oil in mice £ÛJ£Ý.Pharmacol Res,2020,158:104937.
£Û61£ÝWANG TH,TSENG WC,LEU YL,et al.The flavonoid corylin exhibits lifespan extension properties in mouse £ÛJ£Ý.Nat Commun,2022,13(1):1238.
£Û62£ÝMATSON V,CHERVIN CS,GAJEWSKI TF.Cancer and the microbiome-influence of the commensal microbiota on cancer,immune responses, and immunotherapy£ÛJ£Ý.Gastroenterology,2021,160(2):600-613.
£Û63£ÝFENG X,LI Z,GUO W,et al.The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation:A review £ÛJ£Ý.Front Immunol,2023,14:1087755.

Memo

Memo:

National Natural Science Foundation of China£¨No.82074405£©;¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¨±àºÅ£º82074405£©£»¹ú¼ÒÖÐÒ½Ò©¹ÜÀí¾Ö2013Äê¶ÈÖÐÒ½Ò©ÐÐÒµ¿ÆÑÐרÏîÏîÄ¿£¨±àºÅ£º201307006£©

Common functions

Last Update: 2024-01-30